or more transrectal ultrasonography (TRUS)-guided ng/ml and 39% if it was 20.0 ng/ml. of >10 ng/ml have prostate cancer [3], many other
|
|
- Alexandra Oliver
- 5 years ago
- Views:
Transcription
1 BJU International (1999), 83, Elevated serum prostate specific antigen levels in conjunction with an initial prostatic biopsy negative for carcinoma: who should undergo a repeat biopsy? G.C. DURKAN and D.R. GREENE Department of Urology, Sunderland Royal Hospital, Kayll Road, Sunderland, UK Objective To determine the outcome of repeated pros- (31%) had carcinoma on repeat biopsy, 11 after the tatic biopsies in men attending with suspected prostate second and four after a third biopsy. The positive cancer but an initial negative biopsy. repeat biopsy rate was 24% where the PSA level Patients and methods Patients who had undergone two was ng/ml, 33% if the level was or more transrectal ultrasonography (TRUS)-guided ng/ml and 39% if it was 20.0 ng/ml. prostate biopsies were identified from the Hospital There was no significant dicerence in age or initial Information Support System database. Indications for PSA concentration between those men with positive TRUS were a raised prostate-specific antigen (PSA) and those with negative repeat biopsies. However, level (>4.0 ng/ml), with or without an abnormal patients with cancer had significantly higher PSA digital rectal examination (DRE). Sextant prostate levels before repeat biopsy than at first biopsy (P= biopsies plus biopsies of any suspicious hypoechoic ) and had greater PSA velocities than had area or area of DRE abnormality were obtained for patients with no diagnosis of cancer (P=0.0067). histology. Forty-eight patients underwent repeat Conclusion Where subcient clinical suspicion exists, TRUS-guided prostatic biopsies (mean age 67.5, sd despite an initial negative biopsy, repeat TRUS-guided 7.25, range years). prostate biopsies should be carried out to exclude Results The mean (sd, median, range) PSA level was carcinoma of the prostate (13.5, 11.6, ) ng/ml. Fifteen patients Keywords Prostate cancer, PSA, TRUS, biopsy, diagnosis While almost 60% of patients with a serum PSA value Introduction of >10 ng/ml have prostate cancer [3], many other Awareness of prostate cancer has increased among conditions, e.g. BPH, prostatitis, prostatic infarct and patients and GPs because of the increase in prostate prostatic intraepithelial neoplasia (PIN), cause an elevation cancer-related publications in the medical literature and of serum PSA. In contrast, only a quarter of general press in recent years. While the natural history patients with a serum PSA level of 4 10 ng/ml are of prostate cancer is not yet fully known, the availability found to have cancer [4] and many patients will undergo of PSA testing, combined with a greater awareness of unnecessary prostate biopsies as a result. In an attempt prostate cancer, has led to a significant increase in the to refine the sensitivity of PSA as a predictor of prostate referral of patients with an elevated PSA for evaluation. cancer, several PSA derivatives have been studied, Despite a recommendation against screening for the UK including PSA density, PSA velocity and free to total population [1] it is likely that more patients with LUTS PSA ratio. Despite these advances, considerable dibculties will have their PSA level measured, because of concerns may still arise in the detection of prostate cancer, by the patient and/or GP about underlying cancer. This especially in the PSA range of 4 10 ng/ml [5]. will lead to more patients being diagnosed with stage When evaluating a patient with suspected prostate T1c prostate cancer. This factor, combined with the cancer, the accepted diagnostic investigations include a increased incidence of prostate cancer, will provide a DRE, the estimation of serum PSA, and TRUS of the considerable challenge for urologists, although the scale prostate [4,6]. Candidates for such management must of the problem in the UK is unlikely to parallel that in stand to benefit significantly from the diagnosis and the USA where, as a result of screening, new subsequent treatment of their prostate cancer, whether cases of prostate cancer were predicted in 1996 [2]. in terms of improved quality of life, reduced morbidity or prolonged survival. However, many of these patients Accepted for publication 15 July 1998 have no discrete hypoechoic areas visible on TRUS. In BJU International
2 REPEAT BIOPSY FOR SUSPECTED PROSTATE CANCER 35 such cases, the standard procedure has been to take Sunderland Royal Hospital, using the Hybritech sextant biopsies, sampling the base, mid-prostate and Tandem-E assay (Hybritech Inc, San Diego, CA, USA). apex on each side [6]. Unfortunately, despite an elevated Each patient s medical record was carefully reviewed PSA level, abnormal DRE or both, in a significant number and the patient s age, prebiopsy PSA values, PSA velocof cases no cancer is detected on TRUS-guided prostate ity, histopathological diagnosis of each biopsy, DRE biopsy [7 10]. As the volume of prostate sampled by the findings and outcome of each TRUS examination entered standard sextant biopsy technique is relatively small, the into a database and analysed statistically. Data are possibility remains that these individuals may harbour presented as mean (sd) and distributions compared using prostate cancer, despite an initial negative biopsy. As Student s t-test, with significance assumed at P<0.05. yet, no parameters have been agreed that would prevent a patient in this situation undergoing an unnecessary repeat biopsy. The urologist must weigh carefully the Results potential morbidity and associated anxiety of repeat Of the 48 men who underwent repeat TRUS-guided prostatic biopsy against the benefit to the patient of a prostatic biopsies, where their initial biopsy failed to confirmed diagnosis. This issue has been addressed by reveal carcinoma of the prostate, 12 underwent three several studies from the USA [7 10], but has not been and two underwent five biopsies. Overall, 15 (31%) widely discussed in urological literature from the UK. patients had carcinoma on repeat biopsy, 11 after a Thus, the aim of the present study was to investigate second and four after a third biopsy. Histologically, 12 the outcome of repeat prostatic biopsies in men referred of 15 tumours detected were Gleason grade 3+3, while with a clinical suspicion of prostate cancer and persistent the three remaining tumours were Gleason grades 3+2, elevation of PSA, but an initial negative prostate biopsy, 4+3 and 4+5, respectively. The positive biopsy rate and to evaluate which clinical variables are most helpful was 23% (11/48) at the second and four of 14 at the in predicting cancer on repeat biopsy in this group. third biopsy. All patients had an abnormal serum PSA value (>4.0 ng/ml). Their mean PSA was 16.9 (13.5) (median 11.6, range ) ng/ml at the time of Patients and methods their initial biopsy. Fourteen of the 48 men (29%) had Between May 1995 and November 1997, 1059 patients an abnormal DRE, 15 of 48 (31%) had an abnormal attended for TRUS at our institution. We reviewed the TRUS examination and in eight of 48 (17%) both the Hospital Information Support System database and identified DRE and TRUS were abnormal. Based on the outcome 48 men (mean age 67.5 years, sd 7.25, range of their repeat biopsies, seven of the 15 men with a 53 82) with suspected carcinoma of the prostate who positive (cancer detected) repeat biopsy had an abnormal had undergone two or more TRUS-guided prostatic DRE, 10 had an abnormal TRUS and seven had both, biopsies during this period. The indications for TRUS in whereas of the 33 with a negative (cancer not detected) this subgroup of patients were an elevated PSA repeat biopsy, seven (21%) had an abnormal DRE, five (>4.0 ng/ml) with or without an abnormal DRE. A (15%) had an abnormal TRUS and only one had both Bruel and Kjaer system 3535 diagnostic ultrasound unit abnormalities. with a 7 MHz biplanar transrectal probe (model 8551) The histological diagnoses at the first biopsy fell into was used in all examinations. Using the biplanar probe, five main categories, as shown in Table 1; BPH was by the prostate was scanned in both transverse and sagittal far the commonest diagnosis on first biopsy. In five of planes. Sextant biopsies were routinely obtained and a the original 1059 cases (0.5%), the initial biopsies were further two biopsies taken from any area of DRE abnormality reported as inadequate for diagnosis, necessitating or any suspicious hypoechoic area. Biopsies were repeat biopsies. The outcome of the second set of biopsies obtained using an automatic biopsy gun (BioptyA, Bard, in relation to the initial biopsies are also shown in Covington, USA) and 18 G biopsy needles. All TRUS Table 1. There was no significant dicerence in patient examinations were carried out by the same operator age between those with a negative or positive repeat (D.R.G.), either personally or in direct supervision of a biopsy, with mean (sd) age of 69.6 (8.6) and Higher Urological Trainee (7.1) years, respectively (P=0.3311, two-tailed All biopsy material was submitted to the Pathology t-test). Department at Sunderland Royal Hospital and graded The probability of a positive repeat biopsy was 24% by Consultant histopathologists. All patients were given where the serum PSA level was ng/ml, 33% a metronidazole (1 g) suppository after biopsy and were where it was ng/ml and 39% where it was treated for 3 days with amoxicillin/clavulinic acid, or 20.0 ng/ml. There was no significant dicerence ciprofloxacin if allergic to penicillin. PSA was measured between the PSA level at the time of first biopsy in those in all cases by the Department of Chemical Pathology, with a negative or a positive repeat biopsy, with mean
3 36 G.C. DURKAN and D.R. GREENE Table 1 Outcome of first biopsy, and of the second biopsy in relation to histology Outcome of second biopsy* Initial No biopsy* (%) BPH LG PIN HG PIN Cancer Suspicious Prostatitis Inadequate BPH: 25 (52) LG-PIN: 8 (17) HG-PIN: 4 (8) Prostatitis: 6 (13) Inadequate: 5 (10) *LG/HG PIN, Low/high grade prostatic intra-epithelial neoplasia. levels of 15.7 (13.3) and 18.9 (15.1) ng/ml, respectively harbour cancer. Five patients had their second biopsy (P=0.505, two-tailed t-test). However, those men with reported as suspicious (but not diagnostic) of maligcancer on repeat biopsy had significantly higher mean nancy, and of those, two had cancer on their third (sd, range) PSA values before repeat biopsy than at the biopsy. Interestingly, two of eight patients with lowtime of their initial biopsy, at 24.7 (18.3, grade PIN (LGPIN) were found to have cancer on later ) ng/ml and 18.9 (15.1, ) ng/ml, biopsies, but no patient with high-grade PIN (HGPIN) respectively (P=0.0043, two-tailed t-test). Also, those was subsequently found to have cancer. patients with a positive repeat biopsy had significantly higher mean PSA velocities than those with a negative repeat biopsy, at 7.4 (8.9) ng/ml per year and Discussion 1.0 (6.7) ng/ml per year (P=0.0067, two-tailed t- At present, no set criteria exist to guide the urologist in test, Fig. 1). the management of patients with persistently elevated In the 25 men with BPH on first biopsy, nine (36%) serum PSA levels (with or without an abnormal DRE), had cancer on repeat biopsy. There was no dicerence where the initial set of prostate biopsies have been between the positive and negative repeat biopsy groups negative. In the present series, 31% of patients were in initial PSA values, at 16.8 (14.4) and found to harbour cancer on repeat biopsy. This value 17 (12.9) ng/ml, respectively (P=0.486). Of those compares with the series by Fleshner et al. [7], where patients initially in the inadequate for diagnosis cate- 30% of patients had positive repeat biopsies, but is higher gory, two of five had carcinoma on the second and one than the 19 23% quoted by other studies [8 10]. All had carcinoma on the third biopsy. Two patients had authors ultimately recommend repeat prostatic biopsy inadequate second biopsies and of these, one had carciwhere there is a high level of clinical suspicion, despite noma on his next biopsy. Overall, four of seven patients an initial negative biopsy, given the significant initial with inadequate biopsies were subsequently found to false-negative biopsy rate. Fleshner et al. defined a subgroup of patients deemed to be at lowest risk for 30 cancer (PSA<10 ng/ml, PSA density<0.15, PSA velocity<0.75 ng/ml per year, no PIN and a negative DRE, TRUS and no family history) and found that five of 21 (24%) patients in this group had carcinoma on 25 repeat biopsy [7]. Using these parameters, a subset of patients cannot, as yet, be identified for whom repeat biopsy is not required. 20 All the present patients underwent systematic parasagittal TRUS-guided sextant biopsies, as well as directed biopsies of any DRE abnormality or hypoechoic lesion. In view of the high false-negative biopsy rate, this may 15 not be the optimal approach. Eskew et al. [11] described a systematic five-biopsy technique and recommended Time (months) biopsies where the prostate volume was Fig. 1. Comparative PSA velocity (ng/ml per year) for those with <50 ml, and up to 18 biopsies where it was 50 ml; positive (green) and negative (red) repeat biopsies. P= this method increased their cancer detection rate by Mean serum PSA (ng/ml)
4 REPEAT BIOPSY FOR SUSPECTED PROSTATE CANCER 37 35%. Similarly, Levine et al. found that by performing closely in our clinic and will be re-biopsied if there is two consecutive sets of TRUS-guided sextant biopsies at any further significant increase in their serum PSA a single visit, an additional 30% of cancers were levels. detected in the second set of biopsies [12]. In both In an attempt to reduce the number of unnecessary cases, the procedures were well tolerated, with accept- repeat biopsies, several investigators have studied various able complication rates. Using a stochastic computer PSA derivatives as a means of refining PSA sensitivity. simulation of ultrasound-guided biopsies, using math- PSA density was not calculated in the present series, nor ematically reconstructed radical prostatectomy specimens, was free PSA measured, hence their potential impact on Chen et al. [13] found that sextant biopsies only the outcome of repeat biopsies cannot be assessed. There detected cancer in 73% of cases where the total tumour was a significant correlation between PSA velocity and volume was>0.5 ml. Mapping the tumour foci not a positive repeat biopsy (P=0.0067), but as this was detected by the sextant method revealed that these foci calculated by subtracting the PSA level at repeat biopsy were in areas not biopsied by the sextant technique from that at initial biopsy, and adjusting the result to (transition zone, mid-peripheral zone and anterior horn the rate of change over 12 months, rather than recording of peripheral zone). They found that a 10-core biopsy serial measurements of PSA over 18 months to calculate scheme incorporating these additional areas detected velocity, this conclusion may be unreliable. Keetch et al. 96% of cancers. On this evidence, taking more biopsies [18] found that although the combination of PSA density and from more areas of the prostate may reduce the (threshold>0.15) and PSA velocity (>0.75 ng/ml per number of repeat biopsies required in the future. year) could be useful in reducing the number of In the present series, routine transition zone biopsies unnecessary biopsies, they were not subciently sensitive were not taken; there would appear to be some for routine use in cancer detection. justification for this approach in patients with an initial Free PSA has been evaluated recently as a predictor negative biopsy, although this issue remains contro- of prostate cancer in several studies. In a multicentre versial. Lui et al. [14] found that nine of 17 patients trial, Thiel et al. [19] found that a free PSA value of with a positive repeat biopsy had cancer confined to <7% was highly suspicious of prostate cancer, whereas the transition zone. This finding conflicts with the a level of >25% suggested benign disease. In patients results of several other studies that question the with persistently elevated PSA levels, a normal DRE and usefulness of routine transition zone biopsy. Epstein two prior negative biopsies, Morgan et al. [20] found et al. [15] found that the transition zone biopsy alone that a free PSA value of <10% was 91% sensitive and was positive in only 2% of cases, while Bazinet et al. 86% specific in predicting the presence of cancer, and [16] concluded that the low additional yield of transition could help distinguish between BPH and malignancy in zone biopsies precludes their routine use in the detection such patients. Similarly, Catalona et al. [21] found that of prostate cancer. Keetch et al. [17] took transition free PSA thresholds of 28% and 30% detected 90% and zone biopsies in addition to repeat peripheral zone 95% of cancers, respectively, in men with PSA values of biopsies in men who had one or two sets of previous ng/ml, a normal DRE and a prior negative negative biopsies and found that transition zone biopsy biopsy. These studies show that measurement of free detected few additional tumours in this group of PSA provides predictive information about the presence patients. They suggested that cancers located in the of prostate cancer in men with initial negative biopsies transition zone do not usually cause persistently elev- and helps dicerentiate between benign and malignant ated PSA levels in the setting of negative prostate disease. It may prove to be a useful tool in reducing the biopsies. A large randomized prospective trial should number of unnecessary repeat biopsies in such patients resolve this issue. in the future. Of interest in the present series was the lack of In conclusion, the false-negative initial biopsy rate of association between HGPIN and carcinoma on repeat 31% in this selected series is cause for concern and in biopsy. Four of 48 (8%) patients had HGPIN initially, agreement with other authors, as current clinical practice but none were subsequently found to have cancer. stands, we recommend that all patients with persistbut However, two of eight patients with LGPIN had cancer ent elevation of PSA and prior negative biopsies should on repeat biopsy. These findings are similar to those of undergo repeat biopsy, to exclude carcinoma of the Roehrborn et al. [8], who found that no patient with prostate. In view of concerns raised about cancer detection PIN yielded cancer on second biopsy, but contradict by sextant biopsy it would seem appropriate to Ellis and Brawer [9], who found that all five patients in recommend a more extensive biopsy regimen for repeat their series with grade II/III PIN (but none of nine with TRUS-guided biopsies. There are several variables that grade I PIN) had cancer on repeat biopsy. In any event, warrant further evaluation and that may prove useful the present patients with HGPIN are being followed in reducing the need for repeat biopsies; of these, free
5 38 G.C. DURKAN and D.R. GREENE PSA shows greatest promise. However, until large ransets 12 Levine MA, Ittman M, Melamed J, Lepor H. Two consecutive domized clinical trials are conducted to answer these of transrectal ultrasound guided sextant biopsies of the questions, clinicians have no choice but to continue to prostate for the detection of prostate cancer. J Urol 1998; re-biopsy all patients where a high clinical suspicion of 159: Chen ME, Trancoso P, Johnston DA, Tang K, Babaian cancer exists, despite a negative initial biopsy, particu- RJ. Optimisation of prostate biopsy strategy using computer larly in the case of rising PSA velocity. based analysis. J Urol 1997; 158: Lui PD, Terris MK, McNeal JE, Stamey TA. Indications for References ultrasound guided transition zone biopsy in the detection of prostate cancer. J Urol 1995; 153: ECectiveness matters: screening for prostate cancer. NHS 15 Epstein JI, Walsh PC, Sauvageot J, Carter HB. Use of repeat centre for reviews and dissemination, Vol. 2, Issue 2, sextant and transition zone biopsies for assessing extent of Feb prostate cancer. J Urol 1997; 158: CA-Cancer Statistics Atlanta, Georgia. Am Cancer 16 Bazinet M, Karakiewicz PI, Aprikian AG et al. Value of Soc 1996; 46: 5 27 systematic transition zone biopsies in the early detection of 3 Cooner WH, Mosley BR, Rutherford CL Jr et al. Prostate prostate cancer. J Urol 1996; 155: cancer detection in a clinical urological practice by 17 Keetch DW, Catalona WJ. Prostatic transition zone biopsies ultrasonography, digital rectal examination and prostate in men with previous negative biopsies and persistently specific antigen. J Urol 1990; 143: elevated serum prostate specific antigen values. J Urol 4 Catalona WJ, Richie JP, Ahmann FR et al. Comparison of 1995; 154: digital rectal examination and serum prostate specific 18 Keetch DW, McMurtry JM, Smith DS, Andriole GL, Catalona antigen in the early detection of prostate cancer: results of WJ. Prostate specific antigen density versus prostate specific a multicenter clinical trial of 6630 men. J Urol 1994; antigen slope as predictors of prostate cancer in men with 151: initially negative prostate biopsies. J Urol 1996; 156: 5 Masters JG, Keegan PE, Hildreth AJ, Greene DR. Free/total serum prostate specific antigen ratio: how helpful is it in 19 Thiel RP, Oesterling JE, Wojno KJ et al. Multicenter detecting prostate cancer? Br J Urol 1998; 81: comparison of the diagnostic performance of free prostate 6 Selzman AA, Resnick MI. Transrectal ultrasound and specific antigen. Urology 1996; 48: prostate biopsy. Semin Urol 1994; 12: Morgan TO, McLeod DG, Leifer ES, Murphy GP, Moul JW. 7 Fleshner NE, O Sullivan M, Fair WF. Prevalence and Prospective use of free prostate specific antigen to avoid predictors of a positive repeat transrectal ultrasound-guided repeat prostate biopsies in men with elevated total prostate needle biopsy of the prostate. J Urol 1997; 158: specific antigen. Urology 1996; 48: Roehrborn CG, Pickens GJ, Sanders JS. Diagnostic yield of 21 Catalona WJ, Beiser JA, Smith DS. Serum prostate specific repeated transrectal ultrasound-guided biopsies stratified antigen and prostate specific antigen density measurements by specific histopathological diagnoses and prostate specific for predicting cancer in men with prior negative prostatic antigen levels. Urology 1996; 47: biopsies. J Urol 1997; 158: Ellis JW, Brawer MK. Repeat prostate needle biopsy: who needs it? J Urol 1995; 153: Keetch DW, Catalona WJ, Smith DS. Serial prostate biopsies Authors in men with persistently elevated serum prostate specific G.C. Durkan, FRCSI, SHO in Urology. antigen values. J Urol 1994; 151: D.R. Greene, MCh, FRCS(Urol), Consultant Urologist. 11 Eskew AL, Bare RL, McCullough DL. Systematic 5 region Correspondence: Mr D. Greene, Department of Urology, prostate biopsy is superior to sextant method for diagnosing Sunderland Royal Hospital, Kayll Road, Sunderland SR4 carcinoma of the prostate. J Urol 1997; 157: TP, UK.
Are extended biopsies really necessary to improve prostate cancer detection?
(2003) 6, 250 255 & 2003 Nature Publishing Group All rights reserved 1365-7852/03 $25.00 www.nature.com/pcan Are extended biopsies really necessary to improve prostate cancer detection? R Damiano*,1, R
More informationTHE SIGNIFICANCE OF HYPOECHOIC LESION DIRECTED AND TRANSITION ZONE BIOPSIES IN IMPROVING THE DIAGNOSTIC ABILITY IN PROSTATE CANCER
Clinical Urology Brazilian Journal of Urology Official Journal of the Brazilian Society of Urology Vol. 27 (3): 222-226, May - June, 2001 THE SIGNIFICANCE OF HYPOECHOIC LESION DIRECTED AND TRANSITION ZONE
More informationComputer simulated additional deep apical biopsy enhances cancer detection in palpably benign prostate gland
Blackwell Publishing AsiaMelbourne, AustraliaIJUInternational Journal of Urology0919-81722006 Blackwell Publishing Asia Pty Ltd? 200613?12901295Original ArticleAdditional apical biopsy in prostatic gland
More informationCancer. Description. Section: Surgery Effective Date: October 15, 2016 Subsection: Original Policy Date: September 9, 2011 Subject:
Subject: Saturation Biopsy for Diagnosis, Last Review Status/Date: September 2016 Page: 1 of 9 Saturation Biopsy for Diagnosis, Description Saturation biopsy of the prostate, in which more cores are obtained
More informationONCOLOGY LETTERS 8: , 2014
1834 Systematic 12 and 13 core transrectal ultrasound or magnetic resonance imaging guided biopsies significantly improve prostate cancer detection rate: A single center 13 year experience GONG CHENG *,
More informationAlthough the test that measures total prostate-specific antigen (PSA) has been
ORIGINAL ARTICLE STEPHEN LIEBERMAN, MD Chief of Urology Kaiser Permanente Northwest Region Clackamas, OR Effective Clinical Practice. 1999;2:266 271 Can Percent Free Prostate-Specific Antigen Reduce the
More informationTransrectal ultrasound-guided biopsy for the diagnosis of prostate cancer
Transrectal ultrasound-guided for the diagnosis of prostate cancer Adrian Haşegan Clinica de Urologie, Spitalul Clinic Judeţean de Urgenţă Sibiu Facultatea de Medicină Sibiu Abstract Transrectal ultrasound-guided
More informationExtended 12-Core Prostate Biopsy Increases Both the Detection of Prostate Cancer and the Accuracy of Gleason Score
european urology xxx (2005) xxx xxx available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Extended 12-Core Prostate Biopsy Increases Both the Detection of Prostate
More informationThe In uence of Prostate Volume on Prostate Cancer Detection
European Urology Supplements European Urology Supplements 1 (2002) 35±39 The In uence of Prostate Volume on Prostate Cancer Detection Michael K. Brawer * Northwest Prostate Institute, Seattle, USA Abstract
More informationContribution of prostate-specific antigen density in the prediction of prostate cancer: Does prostate volume matter?
ORIGINAL ARTICLE Gulhane Med J 2018;60: 14-18 Gülhane Faculty of Medicine 2018 doi: 10.26657/gulhane.00010 Contribution of prostate-specific antigen density in the prediction of prostate cancer: Does prostate
More informationIntroduction. Key Words: high-grade prostatic intraepithelial neoplasia, HGPIN, radical prostatectomy, prostate biopsy, insignificant prostate cancer
Prostate cancer after initial high-grade prostatic intraepithelial neoplasia and benign prostate biopsy Premal Patel, MD, 1 Jasmir G. Nayak, MD, 1,2 Zlatica Biljetina, MD, 4 Bryan Donnelly, MD 3, Kiril
More informationOwing to the widespread use of prostate specific antigen (PSA)
ORIGINAL RESEARCH Subsequent prostate cancer detection in patients with prostatic intraepithelial neoplasia or atypical small acinar proliferation Moamen M. Amin, MD; Suganthiny Jeyaganth, MSc; Nader Fahmy,
More informationThe Chances of Subsequent Cancer Detection in Patients with a PSA > 20 ng/ml and an Initial Negative Biopsy
Research Article TheScientificWorldJOURNAL (2009) 9, 343 348 TSW Urology ISSN 1537-744X; DOI 10.1100/tsw.2009.47 The Chances of Subsequent Cancer Detection in Patients with a PSA > 20 ng/ml and an Initial
More informationDetection of prostate cancer by MR-ultrasound fusion guided biopsy
Detection of prostate cancer by MR-ultrasound fusion guided biopsy Poster No.: C-0761 Congress: ECR 2014 Type: Scientific Exhibit Authors: T. Durmus, C. Stephan, T. Slowinski, A. Thomas, A. Maxeiner, B.
More informationProstate Cancer Detection and High Grade PIN
Clinical Urology Prostate Cancer Detection and High Grade PIN International Braz J Urol Vol. 37 (1): 87-93, January - February, 2011 doi: 10.1590/S1677-55382011000700011 The Implication of Initial 24-Core
More informationSaturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer
Saturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer Policy Number: 7.01.121 Last Review: 2/2018 Origination: 8/2006 Next Review: 8/2018 Policy Blue Cross and Blue Shield of Kansas
More informationJMSCR Vol 05 Issue 03 Page March 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i3.135 Diagnosis of Carcinoma Prostate Based
More informationSaturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer
Saturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer Policy Number: 7.01.121 Last Review: 2/2019 Origination: 8/2006 Next Review: 8/2019 Policy Blue Cross and Blue Shield of Kansas
More informationTWELVE CORE PROSTATE BIOPSY VERSUS SIX SYSTEMATIC SEXTANT BIOPSIES
Clinical Urology Brazilian Journal of Urology Vol. 28 (3): 207-213, May - June, 2002 Official Journal of the Brazilian Society of Urology TWELVE CORE PROSTATE BIOPSY VERSUS SI SYSTEMATIC SETANT BIOPSIES
More informationIntroduction. Objective To investigate the clinical significance of the 1.13 ng/ml, P<0.001) and a lower free-to-total PSA
British Journal of Urology (1998), 81, 532 538 Free-to-total prostate-specific antigen (PSA) ratio improves the specificity for detecting prostate cancer in patients with prostatism and intermediate PSA
More informationReview of Clinical Manifestations of Biochemicallyadvanced Prostate Cancer Cases
Original Article Review of Clinical Manifestations of Biochemicallyadvanced Prostate Cancer Cases Edmund Chiong, 1,2 Alvin Fung Wean Wong, 2 Yiong Huak Chan 3 and Chong Min Chin, 1,2 1 Department of Surgery,
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationSaturation Biopsy for Diagnosis, Staging, and Management of Prostate Cancer
Saturation Biopsy for Diagnosis, Staging, and Management of Prostate Cancer Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana,
More information10/2/2018 OBJECTIVES PROSTATE HEALTH BACKGROUND THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION
THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION Lenette Walters, MS, MT(ASCP) Medical Affairs Manager Beckman Coulter, Inc. *phi is a calculation using the values from PSA, fpsa and p2psa
More informationUltrasound-guided transrectal extended prostate biopsy: a prospective study
DOI: 10.1111/j.1745-7262.2005.00019.x. Original Article. Ultrasound-guided transrectal extended prostate biopsy: a prospective study Mohammed Ahmed Al-Ghazo, Ibrahim Fathi Ghalayini, Ismail Ibrahim Matalka
More informationGetting to Diagnosis. Debbie Victor Uro-Oncology CNS Royal Cornwall Hospitals Trust
Getting to Diagnosis Debbie Victor Uro-Oncology CNS Royal Cornwall Hospitals Trust GP Visit Symptoms Reduced urinary flow Difficulty starting/stopping Urgency Frequency Nocturia Because a friend/relative
More informationProstate cancer diagnosis: should patients with prostate specific antigen >10 ng/ml have stratified prostate biopsy protocols?
Cancer Detection and Prevention 32 (2009) 34 38 www.elsevier.com/locate/cdp Prostate cancer diagnosis: should patients with prostate specific antigen >0 ng/ml have stratified prostate biopsy protocols?
More informationINTRADUCTAL LESIONS OF THE PROSTATE. Jonathan I. Epstein
INTRADUCTAL LESIONS OF THE PROSTATE Jonathan I. Epstein Topics Prostatic intraepithelial neoplasia (PIN) Intraductal adenocarcinoma (IDC-P) Intraductal urothelial carcinoma Ductal adenocarcinoma High Prostatic
More informationFocus on... Prostate Health Index (PHI) Proven To Outperform Traditional PSA Screening In Predicting Clinically Significant Prostate Cancer
Focus on... Prostate Health Index (PHI) Proven To Outperform Traditional PSA Screening In Predicting Clinically Significant Prostate Cancer Prostate Cancer in Ireland & Worldwide In Ireland, prostate cancer
More informationAPPENDIX. Studies of Prostate-Specific Antigen for Prostate Cancer Screening and Early Detection
APPENDIX D Studies of Prostate-Specific Antigen for Prostate Cancer Screening and Early Detection APPENDIX D: STUDIES OF PROSTATE SPECIFIC ANTIGEN FOR PROSTATE CANCER SCREENING AND EARLY DETECTION: RESEARCH
More informationPost Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series
Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,
More informationHistopathological Study of Transrectal Ultrasound Guided Biopsies of Prostate
ORIGINAL ARTICLE Histopathological Study of Transrectal Ultrasound Guided Biopsies of Prostate in Patients With Raised Serum Prostate Specific Antigen Prabha Rathour 1, Hetal Jani 2, Urvi Parikh 3, Hansa
More informationInpyeong Hwang, Sang Youn Kim, Jeong Yeon Cho, Myoung Seok Lee, Seung Hyup Kim
The diagnostic ability of an additional midline peripheral zone biopsy in transrectal ultrasonography-guided 12-core prostate biopsy to detect midline prostate cancer Inpyeong Hwang, Sang Youn Kim, Jeong
More informationof Nebraska - Lincoln
University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln U.S. Department of Veterans Affairs Staff Publications U.S. Department of Veterans Affairs 8-2000 Detection, Characterization,
More informationOriginal Paper. Urol Int 2013;90: DOI: /
Urologia Internationalis Original Paper Received: January 27, 2012 Accepted after revision: November 26, 2012 Published online: February 13, 2013 Comparison of Transrectal Prostate Biopsy Results with
More informationA re-audit of Prostate biopsies from January to December 2010 and 2013.
A re-audit of Prostate biopsies from January to December 2010 and 2013. Dr. M S Siddiqui Consultant Histopathologist University Hospital of North Tees Stockton on Tees. Objectives To assess and compare
More informationINTEROBSERVER VARIATION OF PROSTATIC VOLUME ESTIMATION WITH DIGITAL RECTAL EXAMINATION BY UROLOGICAL STAFFS WITH DIFFERENT EXPERIENCES
Clinical Urology International Braz J Urol Official Journal of the Brazilian Society of Urology DIGITAL RECTAL EXAMINATION BY UROLOGICAL STAFFS Vol. 30 (6): 466-471, November - December, 2004 INTEROBSERVER
More informationEfficacy of Pelvic Diffusion Weighted MRI Prior to Prostate Biopsy in Patients with tpsa Level of 2,5-20 ng/ml for Determination of Malign Lesions
ISPUB.COM The Internet Journal of Urology Volume 14 Number 1 Efficacy of Pelvic Diffusion Weighted MRI Prior to Prostate Biopsy in Patients with tpsa Level of 2,5-20 ng/ml for Determination of Malign Lesions
More informationCorrelation of Gleason Scores Between Needle-Core Biopsy and Radical Prostatectomy Specimens in Patients with Prostate Cancer
ORIGINAL ARTICLE Correlation of Gleason Scores Between Needle-Core Biopsy and Radical Prostatectomy Specimens in Patients with Prostate Cancer Teng-Fu Hsieh, Chao-Hsian Chang, Wen-Chi Chen, Chien-Lung
More informationBJUI. Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer
2008 The Authors. Journal compilation 2008 BJU International Original Article TEMPLATE-BASED PROSTATE BIOPSY SYSTEM MEGWALU et al. BJUI BJU INTERNATIONAL Evaluation of a novel precision template-guided
More informationUse of early PSA velocity to predict eventual abnormal PSA values in men at risk for prostate cancer {
Use of early PSA velocity to predict eventual abnormal PSA values in men at risk for prostate cancer { (2003) 6, 39 44 ß 2003 Nature Publishing Group All rights reserved 1365 7852/03 $25.00 www.nature.com/pcan
More informationPREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS
ADULT UROLOGY PREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS ABRAHAM MORGENTALER AND ERNANI LUIS RHODEN ABSTRACT Objectives. To determine
More informationThe TRUS guided prostate extended biopsy in the detection of prostate cancer
Mædica - a Journal of Clinical Medicine ORIGIN RIGINAL PAPERS The TRUS guided prostate extended biopsy in the detection of prostate cancer Assoc. Prof. V. AMBERT, MD, PhD; A. ATEIA, MD; I. CHIRA, MD, PhD;
More informationControversies in Prostate Cancer Screening
Controversies in Prostate Cancer Screening William J Catalona, MD Northwestern University Chicago Disclosure: Beckman Coulter, a manufacturer of PSA assays, provides research support PSA Screening Recommendations
More informationRole of Prostate-Specific Antigen Change Ratio at Initial Biopsy as a Novel Decision-Making Marker for Repeat Prostate Biopsy
www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53..46 Urological Oncology Role of Prostate-Specific Antigen Change Ratio at Initial Biopsy as a Novel Decision-Making Marker for Repeat Prostate Biopsy
More informationAge-specific reference ranges for prostate-specific antigen (PSA) in Jordanian patients
(2003) 6, 256 260 & 2003 Nature Publishing Group All rights reserved 1365-7852/03 $25.00 www.nature.com/pcan Age-specific reference ranges for prostate-specific antigen (PSA) in Jordanian patients 1, *
More informationThe Prostate Cancer Detection Rate on the Second Prostate Biopsy according to Prostate-Specific Antigen Trend
www.kjurology.org http://dx.doi.org/1.4111/kju.212.53.1.686 Urological Oncology The Prostate Cancer Detection Rate on the Second Prostate Biopsy according to Prostate-Specific Antigen Trend Hyung-Sang
More informationSignificance of Atypical Small Acinar Proliferation and High-Grade Prostatic Intraepithelial Neoplasia in Prostate Biopsy
www.kjurology.org http://dx.doi.org/1.4111/kju.211.52.11.736 Urological Oncology Significance of Atypical Small Acinar Proliferation and HighGrade Prostatic Intraepithelial Neoplasia in Prostate Biopsy
More informationFisher s exact test for contingency tables. A two-tailed p-value <0.05 was accepted as statistically significant.
BJUI A prospective, randomized trial comparing the Vienna nomogram to an eight-core prostate biopsy protocol Angus Lecuona and Chris F. Heyns Department of Urology, Tygerberg Hospital and University of
More informationProstate Biopsy. Prostate Biopsy. We canʼt go backwards: Screening has helped!
We canʼt go backwards: Screening has helped! Robert E. Donohue M.D. Denver V.A. Medical Center University of Colorado Prostate Biopsy Is cure necessary; when it is possible? Is cure possible; when it is
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More information, De La Taille Alexandre * INSERM : U955, Universit é Paris XII Val de Marne, IFR10, FR. , Universit é Paris XII Val de Marne, Créteil,FR
High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation on initial 21-core extended biopsy scheme: incidence and implications for patient care and surveillance Ploussard
More informationThe Role of TURP in the Detection of Prostate Cancer in BPH Patients with Previously Negative Prostate Biopsy
www.kjurology.org DOI:10.4111/kju.2010.51.5.313 Urological Oncology The Role of TURP in the Detection of Prostate Cancer in BPH Patients with Previously Negative Prostate Biopsy Dae Keun Kim, Sang Jin
More informationProstate MRI Hamidreza Abdi, MD,FEBU Post Doctoral Fellow Vancouver Prostate Centre UBC Department of Urologic Sciences May-20144
Prostate MRI Hamidreza Abdi, MD,FEBU Post Doctoral Fellow Vancouver Prostate Centre UBC Department of Urologic Sciences May-20144 Objectives: Detection of prostate cancer the need for better imaging What
More informationProstate Overview Quiz
Prostate Overview Quiz 1. The path report reads: Gleason 3 + 4 = 7. The Gleason s score is a. 3 b. 4 c. 7 d. None of the above 2. The path report reads: Moderately differentiated adenocarcinoma of the
More informationSince the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationUse of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease
Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate From Benign Prostatic Disease A Prospective Multicenter Clinical Trial William J. Catalona, MD; Alan W. Partin,
More informationDichotomous Estimation of Prostate Volume: A Diagnostic Study of the Accuracy of the Digital Rectal Examination
pissn: 2287-4208 / eissn: 2287-4690 World J Mens Health 2013 December 31(3): 220-225 http://dx.doi.org/10.5534/wjmh.2013.31.3.220 Original Article Dichotomous Estimation of Prostate Volume: A Diagnostic
More informationElevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationEvaluation of Prostate Specific Antigen as a Tumor Marker in Cancer Prostate
Evaluation of Prostate Specific Antigen as a Tumor Marker in Cancer Prostate Pages with reference to book, From 360 To 363 Farkhanda Ghafoor,Shahzad Khan,Bilquis Suleman,Aman Ullah Khan ( Departments of
More informationTumor marker α-fetoprotein receptor does not discriminate between benign prostatic disease and prostate cancer
Original papers Tumor marker α-fetoprotein receptor does not discriminate between benign prostatic disease and prostate cancer Tomaž Smrkolj 1, A F, Borut Gubina 1, B, E, F, Jure Bizjak 1, B, E, F, Kristina
More informationNewer Aspects of Prostate Cancer Underwriting
Newer Aspects of Prostate Cancer Underwriting Presented By: Jack Swanson, M.D. Keith Hoffman, NFP Moments Made Possible Objectives To review and discuss Conflicting messages about PSA testing Cautions
More informationAccurate prediction of the biological potential of. Correlation between the Gleason Scores of Needle Biopsies and Radical Prostatectomy Specimens
Original Article 919 Correlation between the Gleason Scores of Needle Biopsies and Radical Prostatectomy Specimens Biing-Yir Shen, MD; Ke-Hung Tsui, MD; Phei-Lang Chang, MD; Cheng-Keng Chuang, MD, PHD;
More informationISPUB.COM. Interpretation Of Prostatic Biopsies: A Review. A Chitale, S Khubchandani INTRODUCTION NON-NEOPLASTIC LESIONS GRADING: GLEASON'S SCORE
ISPUB.COM The Internet Journal of Urology Volume 3 Number 1 A Chitale, S Khubchandani Citation A Chitale, S Khubchandani.. The Internet Journal of Urology. 2004 Volume 3 Number 1. Abstract The incidence
More informationOriginal Article - Urological Oncology. Ho Gyun Park 1, Oh Seok Ko 1, Young Gon Kim 1, Jong Kwan Park 1-4
www.kjurology.org http://dx.doi.org/10.4111/kju.2014.55.4.249 Original Article - Urological Oncology http://crossmark.crossref.org/dialog/?doi=10.4111/kju.2014.55.4.249&domain=pdf&date_stamp=2014-04-17
More informationBJUI. Follow-up of men with an elevated PCA3 score and a negative biopsy: does an elevated PCA3 score indeed predict the presence of prostate cancer?
. JOURNAL COMPILATION 2010 BJU INTERNATIONAL Urological Oncology FOLLOW-UP OF MEN WITH AN ELEVATED PCA3 SCORE AND A NEGATIVE BIOPSY REMZI ET AL. BJUI BJU INTERNATIONAL Follow-up of men with an elevated
More informationISSN X (Print) Pradesh. *Corresponding author Dr. Ashish
Scholars Journal of Applied Medical Sciences (SJAMS) Sch. J. App. Med. Sci., 2015; 3(8B):2886-2890 Scholars Academic and Scientific Publisher (An International Publisher for Academic and Scientific Resources)
More informationWhat Is the Ideal Core Number for Ultrasound-Guided Prostate Biopsy?
www.kjurology.org http://dx.doi.org/1.4111/kju.214.55.11.725 Original Article - Urological Oncology http://crossmark.crossref.org/dialog/?doi=1.4111/kju.214.55.11.725&domain=pdf&date_stamp=214-11-16 What
More informationAsian J Androl 2005; 7 (2): DOI: /j x
Asian J Androl 5; 7 (2): 159 163 DOI: 1.1111/j.1745-7262.5.29.x. Original Article. Mass screening of prostate cancer in a Chinese population: the relationship between pathological features of prostate
More informationUtility of free/total prostate specific antigen (f/t PSA) ratio in diagnosis of prostate carcinoma
Disease Markers 19 (2003,2004) 287 292 287 IOS Press Utility of free/total prostate specific antigen (f/t PSA) ratio in diagnosis of prostate carcinoma V. Thakur a,, P.P. Singh b, M. Talwar c and U. Mukherjee
More informationORIGINAL ARTICLE. Ja Hyeon Ku 1, Kyung Chul Moon 2, Sung Yong Cho 1, Cheol Kwak 1 and Hyeon Hoe Kim 1
(2011) 13, 248 253 ß 2011 AJA, SIMM & SJTU. All rights reserved 1008-682X/11 $32.00 www.nature.com/aja ORIGINAL ARTICLE Serum prostate-specific antigen value adjusted for non-cancerous prostate tissue
More informationMRI-targeted, transrectal ultrasound-guided prostate biopsy for suspected prostate malignancy: A pictorial review
MRI-targeted, transrectal ultrasound-guided prostate biopsy for suspected prostate malignancy: A pictorial review Poster No.: C-1208 Congress: ECR 2014 Type: Educational Exhibit Authors: J. Murphy, M.
More informationPSA and the Future. Axel Heidenreich, Department of Urology
PSA and the Future Axel Heidenreich, Department of Urology PSA and Prostate Cancer EAU Guideline 2011 PSA is a continuous variable PSA value (ng/ml) risk of PCa, % 0 0.5 6.6 0.6 1 10.1 1.1 2 17.0 2.1 3
More informationPROSTATE MRI. Dr. Margaret Gallegos Radiologist Santa Fe Imaging
PROSTATE MRI Dr. Margaret Gallegos Radiologist Santa Fe Imaging Topics of today s talk How does prostate MRI work? Definition of multiparametric (mp) MRI Anatomy of prostate gland and MRI imaging Role
More informationRepeating an abnormal prostate-specific antigen (PSA) level: how relevant is a decrease in PSA?
Repeating an abnormal prostate-specific antigen (PSA) level: how relevant is a decrease in PSA? Connolly, D., Black, A., Murray, L., Nambirajan, T., Keane, P. F., & Gavin, A. (2009). Repeating an abnormal
More informationEarly outcomes of active surveillance for localized prostate cancer
Original Article ACTIVE SURVEILLANCE FOR LOCALIZED PROSTATE CANCER HARDIE et al. Early outcomes of active surveillance for localized prostate cancer CLAIRE HARDIE, CHRIS PARKER, ANDREW NORMAN*, ROS EELES,
More informationMR-US Fusion Guided Biopsy: Is it fulfilling expectations?
MR-US Fusion Guided Biopsy: Is it fulfilling expectations? Kenneth L. Gage MD, PhD Assistant Member Department of Diagnostic Imaging and Interventional Radiology 4 th Annual New Frontiers in Urologic Oncology
More informationProstate volume predicts high grade prostate cancer both in digital rectal examination negative (ct1c) and positive ( ct2) patients
ORIGINAL ARTICLE Vol. 40 (5): 613-619, September - October, 2014 doi: 10.1590/S1677-5538.IBJU.2014.05.05 Prostate volume predicts high grade prostate cancer both in digital rectal examination negative
More informationHypoechoic Rim of Chronically Inflamed Prostate, as Seen at TRUS: Histopathologic Findings
Hypoechoic Rim of Chronically Inflamed Prostate, as Seen at TRUS: Histopathologic Findings Hak Jong Lee, MD 1 Ghee Young Choe, MD 2 Chang Gyu Seong, MD 3 Seung Hyup Kim, MD 4 Index terms: Prostate Prostate,
More informationProspective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort
European Journal of Cancer (2012) 48, 1809 1815 Available at www.sciencedirect.com journal homepage: www.ejconline.com Prospective validation of a risk calculator which calculates the probability of a
More informationeuropean urology 55 (2009)
european urology 55 (2009) 385 393 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Is Prostate-Specific Antigen Velocity Selective for Clinically Significant
More informationChapter 2. Understanding My Diagnosis
Chapter 2. Understanding My Diagnosis With contributions from Nancy L. Brown, Ph.D.,Palo Alto Medical Foundation Research Institute; and Patrick Swift, M.D., Alta Bates Comprehensive Cancer Program o Facts
More informationPCa Commentary. Executive Summary: The "PCa risk increased directly with increasing phi values."
1101 Madison Street Suite 1101 Seattle, WA 98104 P 206-215-2490 www.seattleprostate.com PCa Commentary Volume 77 September October 2012 CONTENT Page The Prostate 1 Health Index Active Surveillance 2 A
More informationDepartment of Urology, II Clinic, Ankara Numune Education and Research Hospital, Ankara, Turkey 2
International Scholarly Research Network ISRN Urology Volume 2012, Article ID 252846, 5 pages doi:10.5402/2012/252846 Clinical Study The Correlation between Diffusion-Weighted Imaging and Histopathological
More informationScreening for Prostate Cancer Using Prostate-specific Antigen Alone asafirst-linecheckupparameter:resultsofthehealthcheckup System
Jpn J Clin Oncol 2000;30(2)95 100 Screening for Prostate Cancer Using Prostate-specific Antigen Alone asafirst-linecheckupparameter:resultsofthehealthcheckup System Katsunori Uchida 1, Hitoshi Takeshima
More informationAge-specific reference levels of serum prostate-specific antigen and prostate volume in healthy Arab men
Original Article KEHINDE et al. Age-specific reference levels of serum prostate-specific antigen and prostate volume in healthy Arab men ELIJAH O. KEHINDE, OLUSEGUN A. MOJIMINIYI*, MEHRAJ SHEIKH, KALEEL
More informationMRI in the Enhanced Detection of Prostate Cancer: What Urologists Need to Know
MRI in the Enhanced Detection of Prostate Cancer: What Urologists Need to Know Michael S. Cookson, MD, FACS Professor and Chair Department of Urology Director of Prostate and Urologic Oncology University
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationProstate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017
Prostate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017 Dr Puay Hoon Tan Division of Pathology Singapore General Hospital Prostate cancer (acinar adenocarcinoma) Invasive carcinoma composed
More informationBJUI. Clinical staging error in prostate cancer: localization and relevance of undetected tumour areas
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology CLINICAL STAGING ERROR IN PROSTATE CANCER BOLENZ et al. BJUI BJU INTERNATIONAL Clinical staging error in prostate cancer: localization and
More informationDiagnosis and management of prostate cancer in the
Diagnosis and management of prostate cancer in the Jeremy Teoh ( 張源津 ) Assistant Professor, Department of Surgery, The Chinese University of Hong Kong. Email: jeremyteoh@surgery.cuhk.edu.hk Estimated age-standardised
More informationProstate Cancer. Axiom. Overdetection Is A Small Issue. Reducing Morbidity and Mortality
Overdetection Is A Small Issue (in the context of decreasing prostate cancer mortality rates and with appropriate, effective, and high-quality treatment) Prostate Cancer Arises silently Dwells in a curable
More informationUsing Gray-Scale and Color and Power Doppler Sonography to Detect Prostatic Cancer
Using Gray-Scale and Color and Power Doppler Sonography to Detect Prostatic Cancer Ethan J. Halpern 1 Stephen E. Strup 2 OBJECTIVE. We performed a prospective study to assess gray-scale and color and power
More informationPredictive Factors of Gleason Score Upgrading in Localized and Locally Advanced Prostate Cancer Diagnosed by Prostate Biopsy
www.kjurology.org DOI:10.4111/kju.2010.51.10.677 Urological Oncology Predictive Factors of Gleason Score Upgrading in Localized and Locally Advanced Prostate Cancer Diagnosed by Prostate Biopsy Seung Jin
More informationIndividualized prostate biopsy strategy for Chinese patients with different prostate-specific antigen levels
DOI: 10.1111/j.1745-7262.2008.00345.x www.asiaandro.com. Clinical Experience. Individualized prostate biopsy strategy for Chinese patients with different prostate-specific antigen levels Bo Dai 1,4, Ding-Wei
More informationUtility of Prostate MRI. John R. Leyendecker, MD
Utility of Prostate MRI John R. Leyendecker, MD Professor of Radiology and Urology Executive Vice Chair of Clinical Operations Section Head, Abdominal Imaging Wake Forest University School of Medicine;
More informationOriginal Article Optimization of prostate cancer diagnosis by increasing the number of core biopsies based on gland volume
Int J Clin Exp Pathol 2012;5(9):892-899 www.ijcep.com /ISSN:1936-2625/IJCEP1207013 Original Article Optimization of prostate cancer diagnosis by increasing the number of core biopsies based on gland volume
More informationUltrasonographically Guided Biopsy of the Prostate Gland
Review Article Ultrasonographically Guided Biopsy of the Prostate Gland Andrew L. Altman, MD, Martin I. Resnick, MD Abbreviations BPH, benign prostatic hyperplasia; PIN, prostatic intraepithelial neoplasia;
More informationPrognostic value of the Gleason score in prostate cancer
BJU International (22), 89, 538 542 Prognostic value of the Gleason score in prostate cancer L. EGEVAD, T. GRANFORS*, L. KARLBERG*, A. BERGH and P. STATTIN Department of Pathology and Cytology, Karolinska
More information